Phase 1 and 2 of the pioneering clinical trial NCT03056339 enrolling 11 patients with R/R CD19+ malignancies, of which 2 DLBCL patients, showed promising results (74) and indicated the feasibility of adopting CAR-NK therapy for patients with high-risk B cell lymphoma and leukemia. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.